Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...

This overview provides a thorough review of current treatment approaches for first-line management of nononcogenic addicted non–small cell lung cancer. We also address pertinent clinical ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GSK’227, now known as risvutatug rezetecan ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...

A small cell lung cancer (SCLC) misdiagnosis is possible. This can occur because of challenges during the diagnostic tests and because SCLC may share symptoms and causes similar to other conditions.

The Food and Drug Administration (FDA) has granted traditional approval to Imdelltra ® (tarlatamab-dlle) for the treatment of adults with extensive stage small cell lung cancer (ES-SCLC) with disease ...

Small cell lung cancer (SCLC) is rarer than non-small cell lung cancer (NSCLC) but tends to be more difficult to treat. SCLC can be more resistant and aggressive than other cancers, which can increase ...

Chemotherapy is a treatment that may be used for non-small cell lung cancer. It’s often used in combination with other treatment types. Chemotherapy is associated with a variety of risks and benefits.

Early-stage non-small cell lung cancer (NSCLC) offers a better prognosis than advanced stages. Staging helps inform treatment by describing your cancer's size, lymph node involvement, and metastasis.